Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Cross-Sectional Study: Prevalence of Restless Legs Syndrome in Patients With Unpleasant Sensations of the Legs

Completed

Conditions: Restless Legs Syndrome

First Posted Date: 2007-11-12

Last Posted Date: 2009-02-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14956

Registration Number: NCT00557258

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site, Zwickau, Germany

Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2007-11-04

Last Posted Date: 2014-02-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 947

Registration Number: NCT00553267

Locations: 🇧🇬
1235.6.35904 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria
🇮🇪
1235.6.35304 Wilmer Road, Birr, Ireland
🇧🇬
1235.6.35902 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria

and more 94 locations

Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: tenofovir DF 300 mg QD
Drug: emtricitabine 200 mg QD
Drug: Nevirapine 200 mg BID
Drug: Atazanavir 300 mg
Drug: Ritonavir 100 mg

First Posted Date: 2007-11-01

Last Posted Date: 2014-01-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 154

Registration Number: NCT00552240

Locations: 🇺🇸
1100.1512.24 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇺🇸
1100.1512.20 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States
🇺🇸
1100.1512.17 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States

and more 16 locations

Filtered Trial for Telmisartan 40mg Non-responder

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2007-10-30

Last Posted Date: 2014-01-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 314

Registration Number: NCT00550953

Locations: 🇯🇵
1235.14.003 Boehringer Ingelheim Investigational Site, Musashino, Tokyo, Japan
🇯🇵
1235.14.002 Boehringer Ingelheim Investigational Site, Chofu, Tokyo, Japan
🇯🇵
1235.14.004 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan

and more 2 locations

Observational Non-interventional Study With Viramune® in Combination With Truvada® in HIV-infected Patients

Completed

Conditions: HIV Infections

First Posted Date: 2007-10-15

Last Posted Date: 2014-05-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 334

Registration Number: NCT00543803

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site, Wuppertal, Germany
🇩🇪
Boehringer Ingelheim Investigational Site 1, Stuttgart, Germany
🇩🇪
Boehringer Ingelheim Investigational Site 10, Berlin, Germany

and more 13 locations

Observational Non-interventional Study With Spiriva in Chronic Obstructive Pulmonary Disease Patients With Exercise-induced Dyspnoea

Completed

Conditions: Chronic Obstructive Pulmonary Disease

First Posted Date: 2007-10-05

Last Posted Date: 2013-11-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1296

Registration Number: NCT00540163

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site, Zossen, Germany

Non-interventional Observational Study With Pramipexole: Impact on Non-motor Symptoms in Parkinson's Disease

Completed

Conditions: Parkinson Disease

First Posted Date: 2007-10-04

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1192

Registration Number: NCT00539214

Locations: 🇩🇪
Boehringer Ingelheim, Hellenthal, Germany

Observational Non-interventional Study (Anwendungsbeobachtung) With Telmisartan in High-risk Hypertensives

Completed

Conditions: Hypertension
Obesity

First Posted Date: 2007-10-04

Last Posted Date: 2013-11-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 5827

Registration Number: NCT00539487

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site 2, Übach-Palenberg, Germany
🇩🇪
Boehringer Ingelheim Investigational Site 13, München, Germany
🇩🇪
Boehringer Ingelheim Investigational Site 15, München, Germany

and more 91 locations

Non-interventional Observational Study of Pramipexole in Restless Legs Syndrome: Impact on Quality of Life

Completed

Conditions: Restless Legs Syndrome

First Posted Date: 2007-10-04

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2023

Registration Number: NCT00539461

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site, Hellenthal, Germany

Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium
Drug: Salmeterol
Drug: Ciclesonide low
Drug: Ciclesonide high
Drug: Fluticasone
Drug: Placebo

First Posted Date: 2007-09-26

Last Posted Date: 2014-05-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 103

Registration Number: NCT00535366

Locations: 🇧🇪
1249.1.32002 Boehringer Ingelheim Investigational Site, Hasselt, Belgium
🇧🇪
1249.1.32001 Boehringer Ingelheim Investigational Site, Gent, Belgium
🇳🇱
1249.1.31003 Boehringer Ingelheim Investigational Site, Harderwijk, Netherlands

and more 9 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy